Reply to: Severe hypercalcemia as a form of acute lymphoblastic leukemia presentation in children. by Martins, A et al.
Rev Bras Ter Intensiva. 2016;28(2):201-202
Reply to: Severe hypercalcemia as a form of acute 
lymphoblastic leukemia presentation in children
AUTHORS’ RESPONSE
We appreciate your interest in our article.
Hypercalcemia of malignancy in children is in fact well described; however, 
this complication is rare and corresponds to 0.4% - 1.3% of cases of cancer in 
children.(1,2) The risk of fatal outcomes of severe hypercalcemia either due to 
cardiac or neurological complications is also well known. These severe cases 
require aggressive treatment involving volume expansion and treatment with 
calcitonin and bisphosphonates.(3) In the case described, which involved severe 
hypercalcemia and deterioration of the state of consciousness, we opted for 
hyper-hydration and treatment with zoledronate and hemodiafiltration.(4) The 
zoledronate, rather than pamidronate, was preferred because of its greater potency 
and efficacy and shorter period of treatment, as previously described.(5) The 
decision to initiate hemodiafiltration involved the consideration that calcitonin 
is not marketed in Portugal and that the maximum effect of bisphosphonates 
is not observed before two to four days after administration.(5) Therefore, the 
urgent need to reverse the ionic imbalance in a child with a Glasgow coma 
score of 8 led to the performance of hemodiafiltration. It has been reported 
that parathyroid hormone related peptide (PTHrp) is an important mediator 
in hypercalcemia of malignancy and is the mediator most often associated with 
this malignancy,(2,6) which explains its importance in the differential diagnosis 
of hypercalcemia. However, in this case, the dose of PTHrp was 1.2pmol/L 
(reference value < 2.0), as shown in table 2.(4) As reported in Martins et al.,(4) two 
mechanisms are responsible for malignant hypercalcemia: (1) local osteolytic 
lesion (bone metastases) and (2) humoral hypercalcemia via activation of 
the receptor activator of nuclear factor kappa B/receptor activator of nuclear 
factor kappa B ligand (RANK-RANKL). Although PTHrp is the mediator 
most often identified, other mediators may be involved, including interleukin 
(IL)-1, IL-6, tumor necrosis factor (TNF-α), transformation growth factor beta 
(TGF-β), prostaglandins, calcitriol, and PTH that is produced ectopically.(6) 
In addition, the medium- and long-term adverse effects of bisphosphonates 
have been associated with osteonecrosis of the jaw and ectopic deposition of 
calcium.(7) However, to date, no adverse effects related to bisphosphonates have 
been observed in the described case. Nevertheless, hypocalcemia occurred for 
10 days after the initiation of treatment with zoledronate, highlighting the 
need to monitor serum calcium levels two to four weeks after the initiation of 
treatment, which is the period of activity of bisphosphonates.
Resposta para: Hipercalcemia grave como forma de apresentação 
de leucemia linfoblástica aguda em criança
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